CagriSema vs HGH Fragment 176-191
A side-by-side research comparison of CagriSema and HGH Fragment 176-191 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | HGH Fragment 176-191 |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Human Growth Hormone Fragment 176-191 |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Research compound |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Mimics lipolytic action of HGH by stimulating beta-3 adrenergic receptors on adipocytes, increasing cyclic AMP and hormone-sensitive lipase activity. Does not affect IGF-1. |
| Molecular weight | Combination product | 1,817 Da |
| Half-life | 7 days (both components) | 3-4 hours |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 250-500 mcg |
| Frequency | Once weekly | 1-2x daily |
| Route | Subcutaneous | Subcutaneous |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
HGH Fragment 176-191 reported benefits
- Targeted fat loss
- No IGF-1 elevation
- No glucose impairment
- No bone/organ growth effects
- Improved body composition
Related comparisons
Research and educational reference only. Not medical advice.